OpenAI hardware initiative likely to be cut as distraction
OpenAI's hardware device effort (hiring 400 from Apple) is a distraction from core coding value; Apple's trade secret lawsuit may serve as a 'mercy killing' to push Sam Altman to…
Meta is entering the frontier model API market with aggressive low pricing via Spark 1.1, adopting the same business model as OpenAI/Anthropic — a big competitive hit but ROI over…
Anthropic hitting TAM ceiling in software engineering spend
Anthropic's revenue exploded to ~$50B valuation but approaching hard TAM limits — US software engineering spend only $250B total, and Anthropic/OpenAI enterprise revenue already n…
SK Hynix at peak cyclical margins, correction inevitable
SK Hynix and memory peers are massive AI capex beneficiaries trading at 5-8x P/E with 70% net margins, but historically cyclical — prices will correct when new capacity comes onli…
AI drug discovery trajectory uncertain: platform vs biotech model
AI drug discovery companies (Chai, Isomorphic, Latent Labs) raising massive rounds but unclear if they follow platform/LLM economics (winner-take-most) or traditional biotech econ…
Constellation buying pre-AI SaaS at 3x revenue but facing terminal decay
Constellation acquires stalled B2B SaaS at 3x revenue / 12-13x cash flow, but AI-native alternatives are collapsing switching costs (Marketo: renewal cycles from years to days); t…
Marketo in terminal decay, renewal cycles collapsing to days
Adobe's Marketo marketing automation is going to zero — no net new logos, 20% price hikes, API deprecation; Salesforce's LLM lift reduced switching time from one year to one day,…